How to Buy Neuphoria Therapeutics Stock
Neuphoria Therapeutics Inc
Neuphoria Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders.
Neuphoria Therapeutics stock last closed at $4.58, down 2.76% from the previous day, and has increased 77.8% in one year. It has overperformed other stocks in the Biotechnology industry by 1.03 percentage points. Neuphoria Therapeutics stock is currently +111.65% from its 52-week low of $2.16, and -78.6% from its 52-week high of $21.40.
As of Oct 29, 2025, there are 2.36M NEUP shares outstanding. The market value of NEUP is $10.80M. In the past 24 hours, 546,000 NEUP shares were traded.
How to Buy Neuphoria Therapeutics Stock
Wondering how to invest in Neuphoria Therapeutics stock? Here's how.
- Choose where to buy Neuphoria Therapeutics stock: You need to choose an online brokerage, but don't worry - we've tried dozens of online stock brokerages and apps to help you decide where to buy Neuphoria Therapeutics stock.
- Create your brokerage account: Sign up for 0% commission trading with the highest-rated brokerage we've identified.
- Put funds into your investment account: Select your method of payment and add your info.
- Research Neuphoria Therapeutics stock: The Neuphoria Therapeutics ticker symbol is NEUP. Is Neuphoria Therapeutics stock a good investment? Should you buy shares of NEUP? How do NEUP's underlying business fundamentals look? Do top analysts think Neuphoria Therapeutics is a good buy? Why has NEUP's stock price moved recently? (Hint: Our stock market analysis tools can help you understand if NEUP is a good stock to buy).
- Execute your NEUP trade: Decide if you will purchase NEUP shares at the current market price or use a limit order to purchase NEUP stock at a particular price.
- Get key alerts regarding your investment in NEUP: Create a watchlist to watch your position in Neuphoria Therapeutics shares.
Step 1: Choose where to buy Neuphoria Therapeutics stock
You will need an online brokerage account to access the NASDAQ market and buy NEUP stock.
Our favorite brokerage: eToro
We believe that eToro is the best online stock brokerage. Here's why:
- Invest in stocks with 0% commissions: Invest without paying trading commissions.
- Buy fractional shares: Even if you don't have the money to buy a full share, you can still invest in the stock.
- Access to global markets: From Tech to Healthcare, New York to London (for US users, only US stocks are available) — you can fill your portfolio with stocks from the globe's top stock exchanges.
- Social investing: eToro boasts a community with more than 20 million users worldwide. Talk to, learn from, and copy the unique crypto portfolios of other investors.
- Security: eToro is a regulated and licensed fintech leader.
- Buy other assets: Such as ETFs and cryptocurrencies.
Get $10 towards your share purchase by creating an account with eToro now. This offer is only for US users.
Open eToro AccountStep 2: Create your brokerage account
Now that you've picked your brokerage, you need to fill out some personal details so you can invest in NEUP stock today.
How to Open a New Brokerage Account on eToro
- Click here to get started.eToro is a multi-asset investment platform. The value of your investments may go up or down. Your capital is at risk.
- Provide your personal info to start a new brokerage account.
- Send your application by hitting the "Create Account" button. Get started with eToro today
Step 3: Put funds into your investment account
Now that you have filled out your info on app for investing, you can securely and quickly fund your account:
Check out this video walkthrough if you need help transferring funds into your new investment account.
Step 4: Research Neuphoria Therapeutics stock
Once you have identified the best place to buy Neuphoria Therapeutics stock, it's important to analyze their stock before you invest, so you truly comprehend the risk as well as the upside.
Neuphoria Therapeutics stock quick numbers
NEUP Fundamentals
WallStreetZen was designed to help average investors do better fundamental analysis.
You can view all of the due diligence checks on NEUP's stock page.
What is the fair value of NEUP stock?
Analysts use a variety of different financial metrics, analyses, models, and charts to gauge NEUP's fair value.
Using relative valuations ratios:
- NEUP could be undervalued based on its P/B ratio of 0.87x, relative to Biotechnology industry P/B ratio of 4.96x
You can access additional valuation research on NEUP's stock here.
A quick look at NEUP Financials
Positive Financial Indicators:
- NEUP's operating cash flow of $50.48k allows it to safely service it's debt of $76.02k.
- There are more short-term assets than long-term liabilities on the NEUP balance sheet.
- Total NEUP debt is lower than 5 years ago, relative to shareholder equity.
- There are more short-term assets than short-term liabilities on the NEUP balance sheet.
Negative Financial Indicators:
- NEUP has a relatively high debt to equity ratio of 0.51.
- NEUP earnings of -$547.71k is not sufficient to cover its interest payments.
Is it a good time to buy NEUP stock, according to Wall Street analysts?
Out of 2 sell side analysts who research NEUP, the consensus analyst rating on Neuphoria Therapeutics is a Strong Buy
Please keep in mind that analyst ratings are not stock recommendations, nor are they financial advice.
You can dig deeper into what analysts are saying on the Neuphoria Therapeutics stock forecast page.
NEUP Trading Indicators
NEUP Growth Numbers
Last year, NEUP revenue was $10.23M. In the past 5 year, NEUP's revenue has increased by 216.97% per year. This was faster than the Biotechnology industry average of 69.23%.
Find out more about NEUP's earnings and revenue performance here.
Who is buying/selling NEUP?
In the past year, executives and large shareholders at NEUP have bought more shares than they have sold.
Lynx1 Capital Management LP, 10% Owner of NEUP, was the latest NEUP insider to buy. They bought $3,283,108.07 worth of NEUP shares on Oct 21, 2025.
Get more info about who owns NEUP stock here.
Does NEUP stock generate passive income?
No, Neuphoria Therapeutics doesn't provide an income stream by paying out dividends.
Get opinions from other traders
One of the major reasons eToro is our highest-rated brokerage is because of its social trading community.
Click below to learn what other investors have to say.
Step 5: Execute your NEUP trade
There are two main order types:
- Market order: A market order is an order to buy or sell a stock at the best available price.
Market orders are usually the best for newer investors. - Limit order: A limit order is an order to buy or sell a security at a specific price (or better).
If you want to be sure you're buying or selling at a particular dollar amount, place a limit order.
Press the Open button and your broker will execute your order.
If you want additional assistance investing in stocks on eToro, watch the helpful video below:
Step 6: Get key alerts regarding your investment in NEUP
Now that you own some NEUP shares, you'll want to stay up-to-date on your stock purchase.
Create a watchlist to get notified of the latest news about your NEUP stock.
NEUP Feed
How to Buy Stock in Neuphoria Therapeutics
To summarize, here are the 6 steps to buy stock in Neuphoria Therapeutics:
- Choose where to buy Neuphoria Therapeutics stock
- Create your brokerage account
- Put funds into your investment account
- Research Neuphoria Therapeutics stock
- Execute your NEUP trade
- Get key alerts regarding your investment in NEUP
If you are looking for a brokerage, eToro is our recommended option.
Get Started with eToro TodayIf you want to watch your new investment in Neuphoria Therapeutics, add NEUP to your watchlist below.
Related Stock Buying Guides
FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterInformation is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.